| scholarly article | Q13442814 |
| P2093 | author name string | Nancy E Davidson | |
| Madhavi Billam | |||
| Michele D Sobolewski | |||
| P2860 | cites work | Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? | Q22251049 |
| The genomic landscapes of human breast and colorectal cancers | Q27861078 | ||
| DNMT1 and DNMT3b cooperate to silence genes in human cancer cells | Q28212826 | ||
| The epigenomics of cancer | Q28289975 | ||
| Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. | Q32107346 | ||
| Coupling of DNA synthesis and histone synthesis in S phase independent of cyclin/cdk2 activity | Q34153545 | ||
| Clonogenic assay of cells in vitro. | Q34615431 | ||
| Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells | Q35545116 | ||
| Zebularine: a new drug for epigenetic therapy | Q35928384 | ||
| Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology | Q36296406 | ||
| Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine | Q37576837 | ||
| Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment | Q39438664 | ||
| Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine | Q39471085 | ||
| Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides | Q39548154 | ||
| The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells | Q39887368 | ||
| Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines | Q40163040 | ||
| Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. | Q40178236 | ||
| Decitabine activates specific caspases downstream of p73 in myeloid leukemia | Q40367523 | ||
| Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells | Q40424419 | ||
| Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. | Q40448993 | ||
| Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia. | Q40458280 | ||
| Preferential response of cancer cells to zebularine. | Q40523300 | ||
| Epigenomic stress response. Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes | Q40671720 | ||
| Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. | Q41342928 | ||
| Expression of estrogen receptors in estrogen receptor-negative human breast carcinoma cells: modulation of epidermal growth factor-receptor (EGF-R) and transforming growth factor alpha (TGF alpha) gene expression | Q41482030 | ||
| Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells | Q41858565 | ||
| Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase | Q42221528 | ||
| The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor | Q42272315 | ||
| Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells | Q42451074 | ||
| Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells | Q42825623 | ||
| Inhibition of DNA methylation and reactivation of silenced genes by zebularine | Q44346779 | ||
| A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. | Q44657529 | ||
| Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. | Q44885739 | ||
| Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells | Q45299490 | ||
| Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells | Q45540656 | ||
| Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone 1 1Edited by J. Karn | Q58212769 | ||
| Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase | Q67535912 | ||
| Synthesis of 1,3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase | Q71271741 | ||
| Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest | Q73086545 | ||
| Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition | Q73393598 | ||
| Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models | Q79453002 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 581-592 | |
| P577 | publication date | 2009-05-21 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells | |
| P478 | volume | 120 |
| Q34581149 | 3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models |
| Q37354053 | Aberrant promoter CpG methylation and its translational applications in breast cancer. |
| Q84596559 | Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells |
| Q35826334 | Antimetabolite Treatment for Pancreatic Cancer |
| Q35048054 | Augmenting antitumor immune responses with epigenetic modifying agents |
| Q37147428 | Chinese Herbal Mixture, Tien-Hsien Liquid, Induces G2/M Cycle Arrest and Radiosensitivity in MCF-7 Human Breast Cancer Cells through Mechanisms Involving DNMT1 and Rad51 Downregulation. |
| Q34170221 | Comparison of the anti-cancer effect of Disulfiram and 5-Aza-CdR on pancreatic cancer cell line PANC-1 |
| Q28544885 | DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status |
| Q28484901 | DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis |
| Q39671498 | DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer |
| Q34959705 | Demethylating drugs as novel analgesics for cancer pain. |
| Q90222199 | ERα is required for suppressing OCT4-induced proliferation of breast cancer cells via DNMT1/ISL1/ERK axis |
| Q35673407 | Effects of a novel DNA methyltransferase inhibitor Zebularine on human lens epithelial cells |
| Q36095721 | Epigenetic alterations in bladder cancer and their potential clinical implications. |
| Q26828724 | Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments |
| Q91863072 | Epigenetic inhibitor zebularine activates ear pinna wound closure in the mouse |
| Q27694612 | Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response |
| Q38233472 | Epigenetic reprogramming in breast cancer: from new targets to new therapies |
| Q35162148 | Epigenetic therapy for breast cancer |
| Q42316725 | Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma |
| Q37911312 | Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q99583845 | Estrogen receptor α is involved in the regulation of ITGA8 methylation in estrogen receptor-positive breast cancer |
| Q38963653 | Evaluation of wild yam (Dioscorea villosa) root extract as a potential epigenetic agent in breast cancer cells |
| Q36247488 | Folic Acid Inhibits Amyloid β-Peptide Production through Modulating DNA Methyltransferase Activity in N2a-APP Cells |
| Q37854737 | Hypomethylating agents for urologic cancers |
| Q26782613 | Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential |
| Q61814607 | Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy |
| Q64245981 | Landscape of tumor suppressor long noncoding RNAs in breast cancer |
| Q37524412 | Manipulating the epigenome for the treatment of urological malignancies |
| Q44940375 | Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease |
| Q37841589 | New nucleoside analogs for patients with hematological malignancies |
| Q34021985 | Oxidative stress and DNA methylation in prostate cancer |
| Q91936863 | Pharmacological manipulation of DNA methylation normalizes maternal behavior, DNA methylation, and gene expression in dams with a history of maltreatment |
| Q34555935 | Reversibility of membrane N-glycome of HeLa cells upon treatment with epigenetic inhibitors |
| Q35963443 | Role of epigenetic modifications in luminal breast cancer |
| Q34258037 | Targeting DNA methylation for epigenetic therapy |
| Q49544302 | Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer |
| Q42344266 | Targeting tumorigenicity of breast cancer stem-like cells using combination epigenetic therapy: something old and something new |
| Q93047797 | The DNA Methylation Inhibitor Zebularine Controls CD4+ T Cell Mediated Intraocular Inflammation |
| Q39245345 | The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma |
| Q39566623 | The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells |
| Q37772356 | The epigenetics of breast cancer |
| Q38119782 | The promise and failures of epigenetic therapies for cancer treatment |
| Q28079389 | The quest for an effective and safe personalized cell therapy using epigenetic tools |
| Q47193788 | The relationship between DNA methylation and Reprimo gene expression in gastric cancer cells |
| Q39153903 | Zebularine inhibits the growth of A549 lung cancer cells via cell cycle arrest and apoptosis |
| Q53161544 | Zebularine inhibits the growth of HeLa cervical cancer cells via cell cycle arrest and caspase-dependent apoptosis. |
| Q37378689 | Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin. |
| Q35531772 | Zebularine suppresses TGF-beta-induced lens epithelial cell-myofibroblast transdifferentiation by inhibiting MeCP2. |
| Q43979223 | Zebularine-induced apoptosis in Calu-6 lung cancer cells is influenced by ROS and GSH level changes |
Search more.